Related references
Note: Only part of the references are listed.Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose
Lingtian Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
Maria San Roman-Gil et al.
CANCER TREATMENT REVIEWS (2022)
Design and development of photoswitchable DFG-Out RET kinase inhibitors
Yongjin Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
The development of APS03118, a potent next-generation RET inhibitor for treating RET-inhibitor-resistant patients.
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Diagnostics, therapeutics and RET inhibitor resistance for RET fusion?positive non-small cell lung cancers and future perspectives
Chang Lu et al.
CANCER TREATMENT REVIEWS (2021)
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V Subbiah et al.
ANNALS OF ONCOLOGY (2021)
Antitarget Selectivity and Tolerability of Novel Pyrrolo[2,3-d]pyrimidine RET Inhibitors
Casey J. N. Mathison et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
Sara Fancelli et al.
CANCERS (2021)
Fragment-based drug design facilitates selective kinase inhibitor
Zhi-Zheng Wang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2021)
Discovery and optimization of selective RET inhibitors via scaffold hopping
Zhibo Luo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion plus NSCLC and RET-mutant MTC: Phase 1 study results.
Patrick Schoffski et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
Marialuisa Moccia et al.
SCIENTIFIC REPORTS (2021)
Precision therapy for RET-altered cancers with RET inhibitors
Kyaw Z. Thein et al.
TRENDS IN CANCER (2021)
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J. Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma
Casey J. N. Mathison et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804M Kinase
Rebecca Newton et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Advances in Targeting RET-Dependent Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
Marialuisa Moccia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
Naga Rajiv Lakkaniga et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
Arun Kumar Mahato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d] pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant
Xiaoyang Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
Patrick Schoffski et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants
Sean T. Toenjes et al.
ACS CHEMICAL BIOLOGY (2019)
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma
Toyoaki Hida et al.
LUNG CANCER (2019)
506PTPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
A Drilon et al.
ANNALS OF ONCOLOGY (2019)
Functional Studies on Novel RET Mutations and Their Implications for Genetic Counseling for Hirschsprung Disease
Hui Wang et al.
FRONTIERS IN GENETICS (2019)
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon et al.
CANCER DISCOVERY (2019)
A comprehensive review on MEN2B
Frederic Castinetti et al.
ENDOCRINE-RELATED CANCER (2018)
Genetic landscape of papillary thyroid carcinoma in the Chinese population
Jialong Liang et al.
JOURNAL OF PATHOLOGY (2018)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Drug resistance profiles of mutations in the RET kinase domain
Xuan Liu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors
Valeria La Pietra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants
Jiao Yang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer
Roberto Ferrara et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS
Hilary Schenck Eidam et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
A secondary RET mutation in the activation loop conferring resistance to vandetanib
Takashi Nakaoku et al.
NATURE COMMUNICATIONS (2018)
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2018)
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor
Hojong Yoon et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Synthetic Approaches to the New Drugs Approved During 2015
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants
Hojong Yoon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Cell Proliferation and Cytotoxicity Assays
Aysun Adan et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2016)
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
Rebecca Newton et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Drilon et al.
LANCET ONCOLOGY (2016)
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Cristina Romei et al.
NATURE REVIEWS ENDOCRINOLOGY (2016)
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology
Brendan Frett et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma
Elizabeth G. Grubbs et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
A Mass Spectrometry Assay to Simultaneously Analyze ROS1 and RET Fusion Gene Expression in Non-Small-Cell Lung Cancer
Priyanga Wijesinghe et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
Marialuisa Moccia et al.
PLOS ONE (2015)
RET Kinase Inhibitors May Treat Cancer and Gastrointestinal Disorders
Ahmed F. Abdel-Magid
ACS MEDICINAL CHEMISTRY LETTERS (2015)
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis
Motonobu Saito et al.
CARCINOGENESIS (2014)
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation
Brendan Frett et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET
Xinquan Wang
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preparation of 3-Substituted-1-Isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET Kinase Inhibitors
Peter Diner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components
Kunio Mochizuki et al.
HISTOPATHOLOGY (2010)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Synthesis, Modeling, and RET Protein Kinase Inhibitory Activity of 3-and 4-Substituted β-Carbolin-1-ones
Raffaella Cincinelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Ba/F3 cells and their use in kinase drug discovery
Markus Warmuth et al.
CURRENT OPINION IN ONCOLOGY (2007)
RET tyrosine kinase signaling in development and cancer
E Arighi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Direct interactions among Ret, GDNF and GFRα1 molecules reveal new insights into the assembly of a functional three-protein complex
A Amoresano et al.
CELLULAR SIGNALLING (2005)
Share Paper
